Press Releases

Our medical news may contain information about Shionogi products and is therefore intended for medical journalists and health care professionals only. By clicking through to see medical news, you are confirming that you are a medical journalist or healthcare professional.

  1. Jan
  2. Feb
  3. Mar
  4. Apr
  5. May
  6. Jun
  7. Jul
  8. Aug
  9. Sep
  10. Oct
  11. Nov
  12. Dec

June

19 Jun 2019 Release
Shionogi and Ferrer conclude a contract for the promotion in Spain of ▼ Rizmoic® (naldemedine), a therapeutic agent for opioid-induced constipation

May

21 May 2019 Release
Shionogi and Molteni conclude a contract for the commercialisation of Rizmoic® (naldemedine) an Opioid Induced Constipation (OIC) therapeutic agent in Italy and Poland

April

11 Apr 2019 Release
Shionogi Concludes a Contract for the Commercialization of Rizmoic® (naldemedine), an Opioid-Induced Constipation Therapeutic Agent, in Germany, the UK, and the Netherlands
04 Apr 2019 Release Medical News
Shionogi to present clinical data on lusutrombopag at the International Liver Congress™ 2019 of the European Association for the Study of the LIiver (EASL)
03 Apr 2019 Release Medical News
Shionogi to Present New Data at European Congress of Clinical Microbiology and Infectious Diseases 2019.pdf
01 Apr 2019 Release Medical News
Shionogi announces submission of cefiderocol Marketing Authorisation Application

February

22 Feb 2019 Release Medical News
Shionogi announces European Union Marketing Authorisation for lusutrombopag
22 Feb 2019 Release Medical News
Shionogi announces European Union Marketing Authorisation for Rizmoic® (naldemedine)

Select Year

NP-EU-NP-0260 | June 2024